Pancreatic Cancer Research

ResearcherKurume UniversityActive in the last 2 years

Shinichi Yachida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5507-4566; OpenAlex author ID A5010365288. Sources: OpenAlex.

Their work

Papers
23 (first author 6, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
83
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 23

  1. KRAS Mutations in Duodenal Lavage Fluid After Secretin Stimulation for Detection of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006645↗
  2. Efficient and accurate KRAS genotyping using digital PCR combined with melting curve analysis for ctDNA from pancreatic cancer patients. Co-author DOI 10.1038/s41598-023-30131-y↗
  3. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Co-author DOI 10.1093/jjco/hyac110↗
  4. Whole-exome Sequencing Reveals New Potential Susceptibility Genes for Japanese Familial Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000004213↗
  5. Aberrant (pro)renin receptor expression induces genomic instability in pancreatic ductal adenocarcinoma through upregulation of SMARCA5/SNF2H. Co-author DOI 10.1038/s42003-020-01434-x↗
  6. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1038/s41598-019-53271-6↗
  7. Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. First author DOI 10.3390/ijms20030561↗
  8. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines. Co-author DOI 10.1007/s00535-018-1466-y↗
  9. Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling. First author DOI 10.1158/0008-5472.can-16-1208↗
  10. Familial pancreatic cancer: Concept, management and issues. Co-author DOI 10.3748/wjg.v23.i6.935↗
  11. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer. Last author DOI 10.1007/978-3-319-42044-8_3↗
  12. Clinicopathologic Features and Germline Sequence Variants in Young Patients (≤40 Years Old) With Pancreatic Ductal Adenocarcinoma. First author DOI 10.1097/mpa.0000000000000574↗
  13. Germline mutations in Japanese familial pancreatic cancer patients. First author DOI 10.18632/oncotarget.12490↗
  14. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. First author DOI 10.3748/wjg.v22.i38.8480↗
  15. (Pro)renin receptor is crucial for Wnt/β-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep08854↗
  16. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Last author DOI 10.1038/srep18425↗
  17. Genomic alterations in pancreatic cancer and their relevance to therapy. First author DOI 10.4251/wjgo.v7.i10.250↗
  18. Heterogeneity of pancreatic cancer metastases in a single patient revealed by quantitative proteomics. Co-author DOI 10.1074/mcp.m114.038547↗
  19. Evolution and dynamics of pancreatic cancer progression. Co-author DOI 10.1038/onc.2013.29↗
  20. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic… Last author DOI 10.1097/sla.0b013e3182827a65↗
  21. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Co-author DOI 10.1158/1078-0432.ccr-12-1215↗
  22. Novel therapeutic approaches in pancreatic cancer based on genomic alterations. Co-author DOI 10.2174/13816128112092452↗
  23. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. Co-author DOI 10.1371/journal.pone.0022129↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chigusa Morizane · 10 shared papers, 2015–2026 · strength 1.06
  2. Erina Takai · 10 shared papers, 2015–2023 · strength 0.90
  3. Akihiro Ohmoto · 5 shared papers, 2016–2022 · strength 0.48
  4. Susumu Hijioka · 3 shared papers, 2017–2026 · strength 0.41
  5. Junji Furuse · 4 shared papers, 2016–2022 · strength 0.36
  6. Toru Furukawa · 4 shared papers, 2016–2022 · strength 0.32
  7. Reiko Ashida · 2 shared papers, 2017–2026 · strength 0.25
  8. Keiji Hanada · 2 shared papers, 2017–2026 · strength 0.25
  9. Masayuki Kitano · 2 shared papers, 2017–2026 · strength 0.25
  10. Takuji Okusaka · 4 shared papers, 2015–2018 · strength 0.23
  11. Christine A. Iacobuzio–Donahue · 5 shared papers, 2011–2017 · strength 0.23
  12. Kenji Ikezawa · 1 shared paper, 2026 · strength 0.20
  13. Taro Yamashita · 1 shared paper, 2026 · strength 0.20
  14. Kazuo Hara · 1 shared paper, 2026 · strength 0.20
  15. Kazuya Matsumoto · 1 shared paper, 2026 · strength 0.20
  16. Shin Haba · 1 shared paper, 2026 · strength 0.20
  17. Hirokazu Kimura · 1 shared paper, 2026 · strength 0.20
  18. Yohei Takeda · 1 shared paper, 2026 · strength 0.20
  19. Makiko Urabe · 1 shared paper, 2026 · strength 0.20
  20. Hajime Isomoto · 1 shared paper, 2026 · strength 0.20
  21. Kazuyoshi Ohkawa · 1 shared paper, 2026 · strength 0.20
  22. Akinori Shimizu · 1 shared paper, 2026 · strength 0.20
  23. Kazuaki Shimada · 3 shared papers, 2015–2018 · strength 0.18
  24. Nobumasa Mizuno · 2 shared papers, 2017–2022 · strength 0.18
  25. Takeshi Terashima · 2 shared papers, 2017–2022 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.